Different Outcome in COVID-19 Patients with or without PPI Use: A Systematic Review and Meta-analysis
Abstract
Background The coronavirus disease (COVID-19) pandemic still happening and when it’s going to be resolved is not known. In this COVID-19 era, physicians need to better understand the risk and purpose of giving drugs that patients do not need. Proton pump inhibitors (PPI) are sometimes easily prescribed and misused by physicians. The study objective is to find out whether PPI use is associated with better or worse outcomes in patients with COVID-19.
Method We searched retrospective studies in various publication libraries like PubMed, Embase, and CENTRAL from 2020 to 2022. Inclusion criteria were studied which differentiated patients with COVID-19 who regularly used PPI and control which is COVID-19 patients who did not use PPI. That study also needs to report the outcomes. The outcome was then divided into two categories which are good outcomes and worse outcomes consisting of severe COVID-19 needing oxygen therapy, admission to intensive care unit (ICU), acute respiratory distress syndrome (ARDS), shock or mortality, to get each study and total odd ratio (OR), 95% confidence interval, and weight. Studies that did not report the outcomes were excluded. We also analyze the data using a fixed or random effect model accordingly and asses the possibility of publication bias using Egger’s test.
Case Seven of 11 studies with more than 30.000 COVID-19 patients were analyzed in this study. These patients were divided into 2 groups: patients with COVID-19 who were using PPI up to 30 days before being infected and COVID-19 patients who didn’t use PPI before. The total number of patients in the first group is 3531 patients and the second group is 38138 patients. After statistical analysis, we found that the data is heterogenous with p <0,05, I2 94,22% (95%CI 90,44-96,51%) suggesting the OR needs to be determined in the random effect model. We found that pooled OR is 1.99 (p 0.01, 95% CI, 1.18-3.38). Egger’s test for the possibility of publication bias is 0,64 (95%CI -7,24-4,93).
Conclusion COVID-19 patients who use PPI are twice as likely to have a worse outcome than COVID-19 patients who don’t use PPI. This study is statistically significant with a low possibility of publication bias.
References
Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med (Lausanne) 2020; 7:526.
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
Xie Y, Bowe B, Yan Y, et al. Estimates of all-cause mortality and cause-specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:l1580.
Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:76–84. doi:10.1136/gutjnl-2020-322248.
Luxenburger H, Sturm L, Biever P, Rieg S, Duerschmied D, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? JIM 2021; 289;121-124.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W-65–94.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008–12.
Wells G, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2000.
Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020;369:m1996.
Zhou J, Wang X, Lee S, et al. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score- matched territory-wide study. Gut Epub ahead of print: [12 March 2021]. doi:10.1136/gutjnlâ€2020â€323668
McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study. medRxiv 2020.07.23.20160747. doi.org/10.1101/2020.07.23.20160747
Ullah AZMD, Sivapalan L, Kocher HM, Chelala C. COVID-19 in patients with hepatobiliary and pancreatic diseases: A single-centre cross-sectional study in East London. Pancreatology 2020;20;e15.
Ramachandran P, Perisetti A, Gajendran M, Jean-Loius F, Bansal P, et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. medRxiv. 2020. doi: 10.1101/2020.07.12.20151084.
Nguyen PA, Islam M, Galvin CJ, Chang CC, An SY, Yang HC, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. International Journal for Quality in Health Care, 2020, 32(5), 292–299. doi: 10.1093/intqhc/mzaa041
Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009;104:S10–S6.
Laheij RJF, Sturkenboom MCJM, Hassing R- J, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–60.
Buendgens L, Bruensing J, Matthes M, Dückers H, Luedde T, Trautwein C, et al. The administration of proton pump inhibitors in critically ill medical patients is associated with an increased risk of developing Clostridium difficile-associated diarrhoea. J Crit Care 2014; 29:696.e11–696.e15.
Israelsen S.B., Ernst M.T., Lundh A., Lundbo L.F., Sandholdt H., Hallas J., Benfield T. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2021;19:1845–1854.e6.
Pranata R., Huang I., Lawrensia S., Henrina J., Lim M.A., Lukito A.A., Kuswardhani R.A.T., Wibawa I.D.N. Proton pump inhibitor on susceptibility to COVID-19 and its severity: A systematic review and meta-analysis. Pharmacol. Rep. 2021;73:1642–1649. doi: 10.1007/s43440-021-00263-x.
Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Digestive and liver disease 2020;52;1410-1412.
Lee, S. W., Ha, E.K., Yeniova, A. Ö., et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. GUT 0: 1–9 (2020).
Abstract viewed = 72 times
PDF downloaded = 56 times
